There were 841 children in Thailand with growth hormone deficiency (GHD) from January 1992 to 1996. Idiopathic isolated GHD was the major diagnosis. Only 40.19% received recombinant DNA human growth hormone (rhGH) treatment. Also reported here is a 1–2 year study of rhGH therapy in 30 GH-deficient children (21 males, 9 females), aged (mean ± SD) 10.41 ± 3.16 years, and bone age 7.37 ± 3.34 years. The height velocity 1 and 2 years posttreatment were 8.17 ± 1.9 and 7.36 ± 2.8 cm/year respectively, which were statistically significant compared to pretreatment values of 3.91 ± 1.09 cm/year. Improved height SDS was observed at the end of each treatment period. Thyroid function and glycosylated hemoglobin tests were normal during the treatment period. There were no reports of side effects.

Keywords:
Growth hormone, Treatment update, Thailand
1.
Raben MS: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901–903.
2.
Raiti S: Human growth hormone and Creutzfeld-Jakob disease. Ann Intern Med 1985;103:288–290.
3.
Gunnarsson R, Wilton P: Clinical experience with Genotropin worldwide: An update. Acta Paediatr Scand Suppl 1987;337:145–152.
4.
Rasmussen LH, Zachmann M, Nilsson P: Authentic recombinant human growth hormone: Results of a multicenter clinical trial in patients with growth hormone deficiency. Helv Paediatr Acta 1988;43:443–448.
5.
Kaufan BA, Kaufman B, Mapstone TB: Pituitary stalk agenesis magnetic resonance imaging of ‘ectopic posterior lobe’ with surgical correlation. Pediatr Neurosci 1988;14:140–144.
6.
Argyropoulou M, Perignon F, Brauner R, Brunelle F: Magnetic resonance imaging in the diagnosis of growth hormone deficiency. J Pediatr 1992;120:886–891.
7.
George DL, Phillips JA III, Francke U, Seeburg PH: The genes for growth hormone and chorionic somatomammotropin are on the long arm of human chromosome 7 in region q 21 to q ter. Hum Genet 1981;57:138–142.
8.
Spindler SR, Mellon SH, Baxter JD: Growth hormone gene transcription is regulated by thyroid and glucocorticoid hormones in cultured rat pituitary tumor cells. J Biol Chem 1982;257:11627–11631.
9.
Preeyasombat C, Suprasongsin C, Chiranuphab A, Mahachoklertwattana P, Sriphrapradang A, Choubtum L: Congenital complete absence of GH, TSH and PRL in infant: A consequence of pit-1 gene deletion. J Med Assoc Thai 1993;76:232–239.
10.
Yoshifumi I, Tatsumi K, Ogawa M, Kamijo T, Preeyasombat C, Suprasongsin C: Amino N. A novel E 250X mutation of the pit-1 gene in a patient with combined pituitary hormone deficiency. Endocr J 1995;42:351–354.
11.
Clayton PE, Shalet SM: Radiation-induced growth hormone deficiency: Speed of onset is dose dependent. J Pediatr 1991;118:226–228.
12.
Angsusingha K, Suvatte V, Mahasandana C, Tanphaichitr VS: Hormonal and growth status in long-term survivors of acute lymphoblastic leukemia in children. J Med Assoc Thai 1990;73:479–486.
13.
Kastrup KW, Christiansen JS, Andersen KA, Orskov H: Increased growth rate following transfer to daily subcutaneous administration from three weekly intramuscular injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh) 1983;104:148–152.
14.
Albertsson-Wikland K, Westphal O, Westgren U: Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand 1986;75:89–97.
15.
Takano K, Shizume K, Hibi I: A comparison of subcutaneous and intramuscular administration of human growth hormone (hGH) and increased growth rate by daily injection of hGH in GH deficient children. Endocrinol Jpn 1988;35:477–484.
16.
Jorgensen JOL, Moller N, Lauritzen T, Alberti KGMM, Orskov H, Christiansen JS: Evening versus morning injections of growth hormone (GH) in GH-deficient patients: Effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990;70:207–211.
17.
De Muinck Keizer-Schrama SMPF, Rikken B, Wynne HJ, Hokken-Koelega ACS, Wit JM, Bot A, Drop SLS, Dutch Growth Hormone Working Group: Dose-response study of biosynthetic human growth hormone (GH) in GH deficient children: Effects on auxological and biochemical parameters. J Clin Endocrinol Metab 1992;74:899–905.
18.
Tuchinda C, Angsusingha K, Punnakanta L, Likitmaskul S, Thanakitcharu K, Chaichanwatanakul K, Pitukcheewanont P, Wacharasindhu S: Three years of growth hormone therapy in children with growth hormone deficiency. Siriraj Hosp Gaz 1992;44:680–683.
19.
Tuchinda C, Angsusingha Punnakanta L, Likitmaskul S, Wacharasindhu S, Thanalcitcharu K, Pitukcheewanont P: Growth response in Turner syndrome with recombinant human growth hormone therapy. Southeast Asian J Trop Med Public Health 1995;26(suppl 1):142–145.
20.
Ackland FM, Jones J, Buckler JMH, Dunger DB, Rayner PHW, Preece MA: Growth hormone treatment in non-growth hormone-deficient children: Effects of stopping treatment. Acta Paediatr Scand Suppl 1990;366:32–37.
21.
Wacharasindhu S, Likitmaskul S, Punnakanta L, Angsusingha K, Tuchinda C, Chaichanwatanakul K: Short-term treatment with recombinant human growth hormone in idiopathic short stature: Preliminary report. Siriraj Hosp Gaz 1995;47:31–35.
22.
Tanner JM, Whitehouse RH, Takaishi M: Standard from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965; Part II. Arch Dis Child 1966;41:613–635.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.